Videos

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior anatomic outcomes in a real-world analysis of more than 12,000 eyes.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in patients with geographic atrophy due to AMD.

Clinicians unpack anti‑VEGF access barriers—missed visits, step therapy, costs—and how bevacizumab and assistance programs keep patients treated.

Exploring ranibizumab port delivery: long-lasting anti-VEGF control, but surgery, access hurdles and safety tradeoffs make patient selection crucial.

Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Bedside OCT in preterm infants links retinal thickness to motor, cognition, and autism risk at age 2, hinting at earlier brain screening.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Ranibizumab port system delivers anti‑VEGF durability, but surgical risks, access hurdles and patient selection limit wider use.

Andy Chang and Mikhail Boukhny of BVI Medical discuss the company's new Experience Hub in Sant Cugat, Spain, a hands-on training facility built to gather surgeon feedback ahead of the Virtuoso platform's European launch.

Learn how real-world Encelto implantation refines MacTel care, from selecting progressing symptomatic patients to surgical technique, safety counseling, and future ECT promise.

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.

Ectoine eye drops boost tear stability and ease redness and tired eyes, along with burning, foreign body and dryness sensations, offering fast, irritation-free relief for patients with dry eye disease.

How faricimab reshapes DME care: trial vs real-world durability, Ang2/VEGF clues, when to switch, and how AI-guided OCT may help.

Clinical and real-world faricimab data reshape DME treatment strategies, highlighting durability, drying benefits, and when switching therapies may improve outcomes.

Not every question in the management of patients with GA has a clear answer—the two retina specialists work through the ones clinicians face most often in practice.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

Piotr Woźniak, MD, PhD, shares real-world evidence on Artelac Complete in dry eye disease from EuDEC 2026 in Milan, Italy, including improvements in tear break-up time and Schirmer scores, perioperative and contact lens use patterns, and high eye care practitioner satisfaction.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

New aflibercept 8 mg label expands dosing from every 4 to 20 weeks, boosting flexibility, insurance support, and outcomes in tough retinal cases.

High-dose aflibercept 8 mg shows faster fluid drying and longer dosing intervals in AMD, DME and RVO, cutting injections without vision loss.

For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.

SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care.

New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.

Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.

Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in retina, and why lifting others up is just what you do.